TCGA-46-6026-01A-11R-1820-07
— · cohortSQ1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ1
- subtype
- cohortSQ1
- age_years
- 81
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.550
- E2F_TARGETS+0.380
- MYC_TARGETS_V1+0.340
- G2M_CHECKPOINT+0.300
- KRAS_SIGNALING_DN+0.280
- SPERMATOGENESIS+0.240
- HEDGEHOG_SIGNALING+0.140
- WNT_BETA_CATENIN_SIGNALING+0.130
- DNA_REPAIR+0.120
- MITOTIC_SPINDLE+0.090
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.670
- INTERFERON_GAMMA_RESPONSE-0.630
- INFLAMMATORY_RESPONSE-0.530
- ALLOGRAFT_REJECTION-0.520
- IL6_JAK_STAT3_SIGNALING-0.480
- COMPLEMENT-0.470
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.460
- ANGIOGENESIS-0.440
- TNFA_SIGNALING_VIA_NFKB-0.440
- IL2_STAT5_SIGNALING-0.430
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-37-A5EN-01A-21R-A26W-07 | — | cohortSQ2 | 0.949 |
| 2 | TCGA-QK-A8Z7-01A-11R-A39I-07 | — | — | 0.939 |
| 3 | C3N-03886 | — | cohortMD1 | 0.935 |
| 4 | BS_9PB3XH5D | medulloblastoma | — | 0.933 |
| 5 | TCGA-18-4083-01A-01R-1100-07 | — | cohortSQ2 | 0.931 |
| 6 | BS_VPBMDMQX | medulloblastoma | — | 0.931 |
| 7 | BS_3V3KE3VT | medulloblastoma | — | 0.929 |
| 8 | TCGA-BT-A2LA-01A-11R-A18C-07 | — | — | 0.928 |
| 9 | BS_AM70R8RG | medulloblastoma | — | 0.926 |
| 10 | BS_1TWCV047 | Embryonal tumors | — | 0.925 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.550 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.380 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.340 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.280 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.240 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.140 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.130 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.120 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.090 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.030 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.010 | Cobimetinib | — uncovered |